| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nuclear Medicine |
1 From the Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E Medical Center Dr, B1G 505C, Box 0028, Ann Arbor, MI 48109-0028. Received November 18, 1998; revision requested December 22; revision received February 5, 1999; accepted April 29. Supported by National Institutes of Health grants CA53172 and CA52880. Address reprint requests to R.L.W.
PURPOSE: To reevaluate the relationships between standardized uptake values (SUVs) and body weight by using positron emission tomography (PET) with 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG).
MATERIALS AND METHODS: FDG PET scanning was performed in 138 female patients with known or suspected primary breast cancers. SUVs in blood and tumor (n = 79) were calculated by using body weight (SUVbw), ideal body weight (SUVibw), lean body mass (SUVlbm), and body surface area (SUVbsa) on images obtained 50–60 minutes after the injection of FDG.
RESULTS: There was a strong positive correlation between the blood SUVbw and body weight (r = 0.705, P < .001). The blood SUVibw reduced the weight dependence but showed a negative correlation with body weight (r = -0.296, P < .001). Both the blood SUVlbm and SUVbsa eliminated the weight dependence and showed no correlation with body weight (r = -0.010, P = .904 and r = 0.106, P = .215, respectively). Although there was a wide variance in the tumor SUVbw, it showed a weak but significant positive correlation with body weight (r = 0.207, P = .033). Plots of the tumor SUVlbm and SUVbsa versus body weight showed relatively flat slopes.
CONCLUSION: SUVlbm and SUVbsa are weight-independent indices for FDG uptake, and SUVlbm appears to be more appropriate for quantifying FDG uptake to avoid overestimation of glucose utilization in obese patients.
Index terms: Breast neoplasms, PET, 00.12163, 00.32 • Breast neoplasms, radionuclide studies, 00.12163, 00.32 • Fluorine, radioactive • Glucose • Positron emission tomography (PET), 00.12163
This article has been cited by other articles:
|
|
 |
|
  R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis J. Nucl. Med., October 1, 2007; 48(10): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Biswal, D. L. Resnick, J. M. Hoffman, and S. S. Gambhir Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice Radiology, September 1, 2007; 244(3): 651 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Du, I. Cullum, T. M. Illidge, and P. J. Ell Fusion of Metabolic Function and Morphology: Sequential [18F]Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer J. Clin. Oncol., August 10, 2007; 25(23): 3440 - 3447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Guo, H. Zhu, Y. Xi, B. Zhang, L. Li, Y. Huang, J. Zhang, Z. Fu, G. Yang, S. Yuan, et al. Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus J. Nucl. Med., August 1, 2007; 48(8): 1251 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Strauss, J. Lazovic, M. Wintermark, and D. H. Morton Multimodal imaging of striatal degeneration in Amish patients with glutaryl-CoA dehydrogenase deficiency Brain, July 1, 2007; 130(7): 1905 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Thie Use of Anthropometric Factors in 18F-FDG PET Bone Marrow SUVs J. Nucl. Med., November 1, 2006; 47(11): 1901 - 1902. [Full Text] [PDF]
|
|
|
|
|
|
S. Prevost and F. Benard Reply: Use of Anthropometric Factors in 18F-FDG PET Bone Marrow SUVs J. Nucl. Med., November 1, 2006; 47(11): 1902 - 1902. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iagaru and R. Henderson PET/CT follow-up in nonossifying fibroma. Am. J. Roentgenol., September 1, 2006; 187(3): 830 - 832. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bastiaannet, O. S. Hoekstra, W. J. G. Oyen, P. L. Jager, T. Wobbes, and H. J. Hoekstra Level of Fluorodeoxyglucose Uptake Predicts Risk for Recurrence in Melanoma Patients Presenting With Lymph Node Metastases Ann. Surg. Oncol., July 1, 2006; 13(7): 919 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Shankar, J. M. Hoffman, S. Bacharach, M. M. Graham, J. Karp, A. A. Lammertsma, S. Larson, D. A. Mankoff, B. A. Siegel, A. Van den Abbeele, et al. Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials J. Nucl. Med., June 1, 2006; 47(6): 1059 - 1066. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Kenny, D. M. Vigushin, A. Al-Nahhas, S. Osman, S. K. Luthra, S. Shousha, R. C. Coombes, and E. O. Aboagye Quantification of Cellular Proliferation in Tumor and Normal Tissues of Patients with Breast Cancer by [18F]Fluorothymidine-Positron Emission Tomography Imaging: Evaluation of Analytical Methods Cancer Res., November 1, 2005; 65(21): 10104 - 10112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Cheng, A. Mahmood, H. Li, A. Davison, and A. G. Jones [99mTcOAADT]-(CH2)2-NEt2: A Potential Small-Molecule Single-Photon Emission Computed Tomography Probe for Imaging Metastatic Melanoma Cancer Res., June 15, 2005; 65(12): 4979 - 4986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Beckers, C. Ribbens, B. Andre, S. Marcelis, O. Kaye, L. Mathy, M.-J. Kaiser, R. Hustinx, J. Foidart, and M. G. Malaise Assessment of Disease Activity in Rheumatoid Arthritis with 18F-FDG PET J. Nucl. Med., June 1, 2004; 45(6): 956 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Boucher, S. Rodrigue, R. Lecomte, and F. Benard Respiratory Gating for 3-Dimensional PET of the Thorax: Feasibility and Initial Results J. Nucl. Med., February 1, 2004; 45(2): 214 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Wahl, B. A. Siegel, R. E. Coleman, and C. G. Gatsonis Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group J. Clin. Oncol., January 15, 2004; 22(2): 277 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Chin, P. Patel, C. Cohade, M. Ewertz, R. Wahl, and P. Ladenson Recombinant Human Thyrotropin Stimulation of Fluoro-D-Glucose Positron Emission Tomography Uptake in Well-Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 91 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hustinx, C. Lemaire, G. Jerusalem, P. Moreau, D. Cataldo, B. Duysinx, J. Aerts, M.-F. Fassotte, J. Foidart, and A. Luxen Whole-Body Tumor Imaging Using PET and 2-18F-Fluoro-L-Tyrosine: Preliminary Evaluation and Comparison with 18F-FDG J. Nucl. Med., April 1, 2003; 44(4): 533 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Wong, D. T. Lin, H. Schoder, S. G. Patel, M. Gonen, S. Wolden, D. G. Pfister, J. P. Shah, S. M. Larson, and D. H. Kraus Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma J. Clin. Oncol., October 15, 2002; 20(20): 4199 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Miles, M. R. Griffiths, and M. A. Fuentes Standardized Perfusion Value: Universal CT Contrast Enhancement Scale that Correlates with FDG PET in Lung Nodules Radiology, August 1, 2001; 220(2): 548 - 553. [Abstract] [Full Text] [PDF]
|
|
